Policy & Regulation
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
23 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) on Tuesday announced approval from J...
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
23 December 2025 - Clinical-stage immunotherapeutics company Aqualung Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for a Phase 2a study...
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
23 December 2025 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) announced on Monday that it has completed the safety analysis from its proof-of-concept Phase 2, ...
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
23 December 2025 - BrioHealth Solutions, a US-based company developing the BrioVAD System, a Left Ventricular Assist Device (LVAD), announced on Monday that the 100th participant has been enrolled in ...
Neurocrine Biosciences reports Phase 3 study of valbenazine in DCP did not meet primary or key secondary endpoints
23 December 2025 - Neuroscience-focused biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq: NBIX) disclosed on Monday that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and t...
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
22 December 2025 - Finland-based biopharmaceutical company Faron Pharmaceuticals Ltd (AIM:FARN) (First North:FARON) announced on Monday that it has finalised agreements to initiate the Phase I/II BLAZ...